KRAS(G12C) inhibition with sotorasib in advanced solid tumors Journal Article
| Authors: | Hong, D. S.; Fakih, M. G.; Strickler, J. H.; Desai, J.; Durm, G. A.; Shapiro, G. I.; Falchook, G. S.; Price, T. J.; Sacher, A.; Denlinger, C. S.; Bang, Y. J.; Dy, G. K.; Krauss, J. C.; Kuboki, Y.; Kuo, J. C.; Coveler, A. L.; Park, K.; Kim, T. W.; Barlesi, F.; Munster, P. N.; Ramalingam, S. S.; Burns, T. F.; Meric-Bernstam, F.; Henary, H.; Ngang, J.; Ngarmchamnanrith, G.; Kim, J.; Houk, B. E.; Canon, J.; Russell Lipford, J.; Friberg, G.; Lito, P.; Govindan, R.; Li, B. T. |
| Article Title: | KRAS(G12C) inhibition with sotorasib in advanced solid tumors |
| Abstract: | BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. Copyright © 2020 Massachusetts Medical Society. |
| Keywords: | aged; middle aged; genetics; mutation; clinical trial; dose response; antineoplastic agents; antineoplastic agent; neoplasm; neoplasms; carcinoma, non-small-cell lung; lung neoplasms; dose-response relationship, drug; colorectal neoplasms; lung tumor; multicenter study; colorectal tumor; phase 1 clinical trial; protein p21; proto-oncogene proteins p21(ras); kras protein, human; non small cell lung cancer; humans; human; male; female |
| Journal Title: | New England Journal of Medicine |
| Volume: | 383 |
| Issue: | 13 |
| ISSN: | 0028-4793 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 2020-09-24 |
| Start Page: | 1207 |
| End Page: | 1217 |
| Language: | English |
| DOI: | 10.1056/NEJMoa1917239 |
| PUBMED: | 32955176 |
| PROVIDER: | scopus |
| PMCID: | PMC7571518 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work